logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • beta Lactamase Inhibitor class drugs

    FiltersReset Filters
    10 results

    • ampicillin and sulbactam

      (Ampicillin Sodium and Sulbactam Sodium)
      Eugia US LLC
      Usage: Ampicillin and sulbactam for injection is indicated for treating infections from susceptible microorganisms in skin and skin structure infections, intra-abdominal infections, and gynecological infections. It is effective against beta-lactamase producing strains of various bacteria, while also addressing mixed infections involving ampicillin-susceptible organisms.

    • ampicillin sodium and sulbactam sodium

      (ampicillin sodium, sulbactam sodium)
      Armas Pharmaceuticals Inc.
      Usage: Ampicillin and sulbactam for injection is indicated for treating skin and skin structure infections, intra-abdominal infections, and gynecological infections caused by beta-lactamase producing organisms, including specific strains of Escherichia coli, Klebsiella, Bacteroides, and others. It is also effective against ampicillin-susceptible organisms.

    • avycaz

      (ceftazidime, avibactam)
      Allergan, Inc.
      Usage: AVYCAZ (ceftazidime and avibactam) is indicated for treating complicated intra-abdominal and urinary tract infections, including pyelonephritis, as well as hospital-acquired and ventilator-associated bacterial pneumonia. It targets susceptible gram-negative bacteria in adult and pediatric patients (≥31 weeks gestational age).

    • piperacillin and tazobactam

      (piperacillin and tazobactam)
      Armas Pharmaceuticals Inc.
      Usage: Piperacillin and tazobactam is indicated for treating intra-abdominal infections, nosocomial pneumonia, skin and skin structure infections, female pelvic infections, and moderate community-acquired pneumonia in adults and pediatric patients (2 months and older), specifically targeting beta-lactamase producing bacteria.

    • piperacillin and tazobactam

      (Piperacillin and Tazobactam)
      Sandoz Inc
      Usage: Piperacillin and tazobactam for injection is indicated for treating intra-abdominal infections, nosocomial pneumonia, skin infections, female pelvic infections, and community-acquired pneumonia in patients aged 2 months and older. It targets infections caused by beta-lactamase producing bacteria, aiming to reduce drug resistance.

    • piperacillin and tazobactam

      (piperacillin and tazobactam)
      Armas Pharmaceuticals Inc.
      Usage: Piperacillin and tazobactam is indicated for treating intra-abdominal and nosocomial pneumonia in adults and pediatric patients, as well as skin infections, female pelvic infections, and moderate community-acquired pneumonia, particularly when caused by specific beta-lactamase producing bacteria. It should be used judiciously to prevent drug resistance.

    • piperacillin and tazobactam

      (piperacillin sodium and tazobactam sodium)
      Civica, Inc.
      Usage: Piperacillin and tazobactam is indicated for treating intra-abdominal infections, nosocomial pneumonia, skin infections, female pelvic infections, and community-acquired pneumonia in patients 2 months and older, specifically those caused by beta-lactamase producing bacteria. It aims to reduce drug-resistant bacteria development.

    • vabomere

      (Meropenem-Vaborbactam)
      Melinta Therapeutics, LLC
      Usage: VABOMERE® is indicated for treating complicated urinary tract infections (cUTI), including pyelonephritis, in patients 18 and older, caused by susceptible bacteria such as E. coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex. It aims to reduce drug-resistant bacteria development.

    • xacduro

      (sulbactam and durlobactam)
      LaJolla Pharmaceutical Company
      Usage: XACDURO is indicated for treating hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in adults, caused by susceptible strains of Acinetobacter baumannii-calcoaceticus. It should only be used for infections proven or suspected to be due to these bacteria to prevent drug resistance.

    • zerbaxa

      (ceftolozane and tazobactam)
      Merck Sharp & Dohme LLC
      Usage: ZERBAXA is indicated for the treatment of complicated intra-abdominal infections, complicated urinary tract infections (including pyelonephritis), and hospital-acquired or ventilator-associated bacterial pneumonia in adults and pediatric patients, targeting specific susceptible Gram-negative and Gram-positive bacteria. Usage should be guided by culture results and epidemiology.